Search

Displaying results 5891 - 5900 of 10000 in total
  1. Drug

    LM-609

    go.drugbank.com/drugs/DB05787
    Experimental

    LM-609 (Vitaxin) is an artificial antibody that targets a protein on the surface of newly forming blood vessels, as well as on certain tumors.

  2. Drug

    Sebelipase alfa

    go.drugbank.com/drugs/DB11563
    ApprovedInvestigational

    [L39337] Sebelipase alfa is a recombinant form LAL approved for the treatment of LAL deficiency. … In addition, patients with LAL deficiency typically develop dyslipidemia, which itself contributes to a number of adverse cardiovascular outcomes.

  3. Drug

    Enlicitide

    go.drugbank.com/drugs/DB22580
    ApprovedInvestigational

    [L63795] Unlike the monoclonal antibody PCSK9 inhibitors ([evolocumab], [alirocumab]), enlicitide is administered orally as a once-daily tablet. … [L63795] Enlicitide is indicated as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), and was studied in

  4. Drug

    Pagoclone

    go.drugbank.com/drugs/DB04903
    Investigational

    Pagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other more well known drugs such as the sleeping medication zopiclone. … It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures

  5. Drug

    Drinabant

    go.drugbank.com/drugs/DB05750
    Investigational

    AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.

  6. Drug

    TTP889

    go.drugbank.com/drugs/DB05131
    Investigational

    TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. … TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system.

  7. Drug

    Brotizolam

    go.drugbank.com/drugs/DB09017
    ApprovedWithdrawn

    Brotizolam is an extremely potent drug and it is rapidly eliminated with an average half-life of 4.4 hours (range 3.6 - 7.9 hours). … Brotizolam is a sedative-hypnotic thienodiazepine drug which is a benzodiazepine analog. It demonstrates anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant effects.

  8. Drug

    MUC1 Dendritic Cell Vaccine

    go.drugbank.com/drugs/DB05477
    Investigational

    Dendritic Cell (DC) Therapy is a newly emerging and potent form of immune therapy that amplifies the actions of the body's own immune system to help fight cancer, AIDS and other serious conditions. … These cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer.

  9. Drug

    Amolimogene bepiplasmid

    go.drugbank.com/drugs/DB04904
    Investigational

    Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia. … Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV).

  10. Drug

    Arecoline

    go.drugbank.com/drugs/DB04365
    Experimental

    It is used in the form of various salts as a ganglionic stimulant, a parasympathomimetic, and a vermifuge, especially in veterinary practice. It has been used as a euphoriant in the Pacific Islands. … An alkaloid obtained from the betel nut (Areca catechu), fruit of a palm tree. It is an agonist at both muscarinic and nicotinic acetylcholine receptors.